4.1.14 Participation in registers Estimated reading: 3 minutes 666 views Authors Goal and purpose Treatment data should be submitted to registries in anonymised form in order to gain insights into the effectiveness and safety of treatment procedures, such as cancer registries. Only in this way can experience be gathered beyond the hospital itself and contribute to the improvement of hospital services. Confidentiality and data protection should be guaranteed.The aggregation of the data can be used for your own quality control and evaluation. Comparisons can be made with other service providers. Application Participation is determined by management. The specialist department is responsible for transmitting the data, analysing and drawing conclusions from the results. See 4.3.05 Evaluation of central registers Description of the process Examples: German Resuscitation Register https://www.reanimationsregister.de The German Resuscitation Registry (GRR) is the largest supra-regional database for the collection, evaluation and assessment of resuscitations in emergency medical services and hospitals, as well as of in-hospital emergency care in German-speaking countries. It is one of the most important and forward-looking instruments for optimising emergency care for patients in cardiovascular arrest. Since the official launch of the German Resuscitation Register under the auspices of the German Society for Anaesthesiology and Intensive Care Medicine (DGAI) in May 2007, more than 480,000 data records of out-of-hospital and in-hospital resuscitated patients as well as emergency care in hospitals and primary death determinations have been recorded in the database. MS register The MS register In 2001, the German Multiple Sclerosis Society (DMSG) initiated the establishment of a Multiple Sclerosis Registry (MS Registry) for Germany. MS Forschungs- und Projektentwicklungs-gGmbH (MSFP) was founded to operate the MS register. In 2005, the MS Registry went into regular operation and has been continuously expanded and developed ever since. Most recently, almost 13,000 patients were registered annually by the centres recognised by the DMSG, with an average of two consultations per patient per year. REGIMS REGIMS is an immunotherapy registry to improve drug safety in MS therapy. The primary objective is to record the frequency, type, characteristics and effects of side effects of current and new immunotherapeutic agents in the routine clinical treatment of MS. Secondary objectives include the evaluation of factors that are associated a) with side effects and b) with good adherence to therapy. In addition to documentation by the treating physician, all included patients will participate in an additional survey regarding their subjective evaluation of the course of the disease. Risks Resources Material Time required Documentation Responsibility and qualification Notes and comments Applicable documents Literature National Clinical Quality Registry ProgrammeThe Australian Government is investing $40 million over 4 years to set up a National Clinical Quality Registry Programme. Terms Attachments 4.1 Documentation - Previous 4.1.13 Classification systems Next - 4.1 Documentation 4.1.15 Tumour documentation
